Mark Yarmarkovich

Mark Yarmarkovich, PhD, currently serves as Principal Investigator and Assistant Professor at NYU Langone Health since January 2023 and as Senior Scientist at the Children's Hospital of Philadelphia since August 2019, where previous roles included Postdoctoral Scientist. In addition, Mark founded Tantigen Bio in February 2021 and is a scientific co-founder of Hula Therapeutics since September 2020. Educational credentials include a PhD in Cell and Molecular Biology - Cancer from the University of Pennsylvania School of Medicine (2012-2019) and a B.S. in Biomedical Engineering from the University of Wisconsin-Madison (2003-2007). Prior experience comprises a research associate role at Genentech where Mark worked on antibody-drug conjugates and a two-year rotational engineering program, as well as engineering work at Harvard Medical School and research internships at Genentech and the Howard Hughes Medical Institute. Mark's thesis centered on tumor target discovery and T-cell engineering, reflecting a strong focus on oncology and biomedical research throughout the career.